EUCTR2019-002267-10-GR进行中（未招募）1 期
A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A participant will be eligible for inclusion in the study if the participant:
- •1. Has a diagnosis of possible, probable, or proven IA per 2020
- •EORTC/MSG disease definitions.
- •2. If enrolled with a possible or probable IA diagnosis, has one or more of the following risks as per 2020 EORTC/MSG disease definitions:
- •- Recent history of neutropenia (<0.5 × 109 neutrophils/L [<500
- •neutrophils/mm3]) (within 30 days before to screening).
- •- Receipt of an allogeneic HSCT.
- •- Receipt of a solid organ transplant.
- •- Hematologic malignancy currently under treatment or has been treated in the recent past.
- •- Treatment with other recognized T-cell immunosuppressants, such as calcineurin inhibitors, TNF-a blockers, specific monoclonal antibodies(such as alemtuzumab), or nucleoside analogues during the past 90 days.
- •- Prolonged use corticosteroids for =3 weeks in the past 60 days (average minimum dose of =0.3 mg/kg/day of prednisone equivalent).
- •- Congenital or inherited severe immunodeficiency (including but not limited to chronic granulomatous disease, STAT 3 deficiency, CARD9 deficiency, STAT-1 gain of function, or severe combined
- •immunodeficiency).
- •- Treatment with recognized B-cell immunosuppressants, such as
- •Bruton's tyrosine kinase inhibitors, eg, ibrutinib.
- •- Acute graft-versus-host disease grade III or IV involving the gut,
- •lungs, or liver that is refractory to first-line treatment with steroids.
- •3. If enrolled with a possible or probable IA diagnosis, meets mycologic and clinical criteria as per 2020 EORTC/MSG disease definitions:
- •- Possible IA includes participants with clinical criteria, with the
- •anticipation that further diagnostic workup is in progress as clinically feasible and may result in updated classification of the invasive fungal infection as per the 2020 EORTC/MSG disease definitions.
- •- Probable IA includes participants with clinical criteria, along with mycological criteria including serum, plasma, CSF, or BAL fluid Aspergillus galactomannan antigen, or Aspergillus PCR test positive in plasma, serum, whole blood, or BAL fluid, or evidence of Aspergillus by histology or microscopy, or positive culture of a specimen taken by nonsterile sampling of an infected site as per 2020 EORTC/MSG disease definitions.
- •4. If enrolled with a proven IA diagnosis, has demonstrated fungal elements (by cytology, microscopy, or histopathology, including Aspergillus nucleic acid probe where available) or positive culture for Aspergillus of a tissue specimen obtained from an otherwise sterile site as per 2020 EORTC/MSG disease definitions.
- •5. Has a central line (eg, central venous catheter, peripherally-inserted central catheter) in place or planned to be in place before beginning IV study treatment.
- •6. Has clinical symptoms consistent with an acute episode of IA, defined as duration of clinical syndrome of <30 days.
- •7. Is male or female, and =2 years of age and <18 years of age at the time of first dose of study treatment and weighs at least 10 kg. Participants may be of any race/ethnicity.
- •8. Male participants are eligible to participate if they agree to the
- •following during the intervention period and for at least 30 days] after the last dose of study treatment:
- •- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
- •- Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause Appendix 5) as det
排除标准
- •The participant must be excluded from the study if the participant:
- •1. Has chronic (=30 days’ duration) IA, relapsed/recurrent IA, or refractory IA that has not responded to prior antifungal treatment.
- •2. Has cystic fibrosis, pulmonary sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
- •3. Has known hypersensitivity or other serious adverse reaction to any azole antifungal therapy, or to any other ingredient of the study treatment used.
- •4. Has any known history of torsade de pointes, unstable cardiac arrhythmia or proarrhythmic conditions, a history of recent myocardial infarction, congenital or acquired QT prolongation, or cardiomyopathy in the context of cardiac failure within 90 days of time of first dose of study treatment.
- •5. Has known hereditary fructose intolerance.
- •6.Has known galactose intolerance, Lapp lactase deficiency, or glucosegalactose malabsorption.
- •7. Is on artificial ventilation at the time of first dose of study treatment.
- •8. Has any condition that, in the opinion of the investigator, may
- •interfere with optimal participation in the study.
- •9. Has received any treatment specifically listed in Table 2 within the specified timeframes before the start of study treatment
- •10. Has enrolled previously in the current study and been discontinued.
- •11. Has QTc prolongation (based on either Fridericia or Bazett's
- •correction) at screening >500 msec.
- •12. Has significant liver dysfunction (defined as total bilirubin >1.5 × ULN AND AST or ALT >3 × ULN with normal alkaline phosphatase) at screening.
- •13. Has calculated creatinine clearance <20 mL/min (Cockroft-Gault formula) or<20 mL/min/1.73 m2 (modified Schwartz formula) at screening.
- •14. Is not expected, in the opinion of the investigator, to survive for at least 1 month after the initiation of study treatment.
- •15. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
研究者
相似试验
进行中（未招募）
1 期
Posaconazole (MK-5592) IV and oral in children with invasive aspergillosisInvasive aspergillosis (IA)MedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 100000004862EUCTR2019-002267-10-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.30
进行中（未招募）
1 期
Posaconazole (MK-5592) IV and oral in children with invasive aspergillosisInvasive aspergillosis (IA)MedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 100000004862EUCTR2019-002267-10-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.30
进行中（未招募）
1 期
Posaconazole (MK-5592) IV and oral in children with invasive aspergillosisInvasive aspergillosis (IA)MedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-002267-10-Outside-EU/EEAMerck Sharp & Dohme LLC
进行中（未招募）
1 期
Posaconazole (MK-5592) IV and oral in children with invasive aspergillosisEUCTR2019-002267-10-BEMerck Sharp & Dohme LCC30
招募中
不适用
POSACONAZOLE (MK-5592) IV AND ORAL IN CHILDREN WITH INVASIVE ASPERGILLOSIS.-B44 AspergillosisB44AspergillosisPER-039-19Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,